Participated · Seed · Mar 2026

Laigo Bio is developing the SureTACs platform to generate bispecific antibodies that selectively degrade disease-causing membrane proteins by pairing an E3 ligase with a target protein to trigger ubiquitination and lysosomal degradation. The approach is intended to enable highly selective elimination of disease-driving membrane targets and to produce first-in-class, dual-targeted therapies. Laigo is focusing its programs on oncology as well as autoimmune and immunology indications, including graft rejection, and is advancing multiple candidate programs. The company reports in vivo and in vitro efficacy with a claimed high degree of selectivity and improved toxicity and safety. Laigo is advancing its oncology pipeline toward clinical development and progressing three autoimmune/immunology programs with support from its recent seed financing.

Participated · Series A · Oct 2025

Trogenix is a biotechnology company focused on creating “one-and-done” treatments for aggressive solid tumours through its Odysseus platform. The platform combines genomics, oncology, immunotherapy and gene therapy, using AAV vectors to deliver proprietary Synthetic Super-Enhancers (SSEs) directly into tumour cells while evading immune detection. These SSEs precisely regulate gene expression to expose cancer cells to the immune system and trigger tumour cell death. If residual tumour cells persist, the approach acts as a ‘Trojan horse’ to counter recurrence. Founded by life-science investor 4BIO, the company aims to advance a pipeline of potentially curative therapies toward clinical trials. Trogenix is led by CEO Ken Macnamara and is headquartered in Edinburgh, Scotland. The new capital positions the company to accelerate pre-clinical research and move multiple candidates into the clinic.

Participated · Series A · Sep 2025

AiM Medical Robotics is building a compact, portable robotic platform that operates directly inside an MRI scanner, giving neurosurgeons continuous, real-time imaging while they position instruments. The technology targets deep-brain stimulation lead placement for Parkinson’s disease and other movement disorders, and can be adapted for cranial biopsies, tumor and epilepsy ablations, and targeted intracranial drug delivery. By eliminating the need to shuttle patients between the operating room and imaging suite, the system seeks to make procedures faster, safer, and more precise, lowering both risk and cost. The company plans to layer artificial intelligence onto the platform so it can learn from surgical data, optimize workflows, and provide predictive guidance. AiM estimates its initial DBS market opportunity at $7.9 billion. Including the new capital, the company has secured over $11.3 million in equity funding, supplemented by significant federal grants. The fresh funds will support first-in-human trials, regulatory progress, and expansion of strategic partnerships.

Participated · Equity · Dec 2024

52North is a Cambridge, UK-based med-tech company developing low-cost products to streamline urgent care pathways in oncology and improve patient safety across socio-economic groups. Its flagship product, Neutrocheck®, was granted breakthrough status by the UK Government under the Innovative Devices Access Pathway earlier this year. The company's products are still in development, have not been authorised by regulators and are not currently available for sale. 52North plans to use the £4.72M in newly raised funding to advance its products toward market. Founded in 2018 by University of Cambridge postgraduates, the company focuses on urgent care pathways in oncology. 52North, founded in 2018 and based in Cambridge, develops Neutrocheck, a portable device plus app that enables cancer patients to test their risk of life-threatening neutropenic sepsis at home or in clinical settings. The company’s mission is to improve health outcomes and health equity by reinventing care pathways. 52North was named Medtech Company of the Year at the 2023 Cambridge Independent Science & Technology Awards. It has joined two major US accelerator programmes — Cedars‑Sinai and Texas Medical Centre — and is participating in a US incubator to drive international expansion. Participation in those programmes, funded in part by Innovate UK’s Global Business Incubator programme, has included over 50 mentor interactions with clinicians and insurers to refine the US value proposition. The company has engaged in industry events and collaborations, including presentations at HLTH and the Texas Life Sciences Forum and a new collaboration with Cedars‑Sinai’s Tatonetti Lab; financially it received a $100,000 investment from Cedars‑Sinai alongside other investors. Founded in 2018 and based in the UK, 52 North Health has developed NeutroCheck, a small portable device paired with a digital platform that assesses neutropenic sepsis risk from a blood finger-prick. The solution aims to triage patients at home so at-risk patients are prioritised for urgent care while low-risk patients can avoid unnecessary A&E visits. The company plans to incorporate UnifAI Technology’s AI-powered digital reader into the solution and to progress through its first clinical trial. With a new grant from Innovate UK, the startup will scale development, hit key clinical milestones and prepare for clinical validation. The clinical validation study is expected to begin next summer and involve about 250 patients, followed by an at-home test of the device for around 30 patients. Results will support a regulatory submission for UKCA and CE marking and build evidence to enable NHS roll-out. 52 North Health developed NeutroCheck, a low-cost clinical AI point-of-care device and digital platform for at-home monitoring of neutropenic sepsis risk in cancer patients. The company says NeutroCheck improves safety, quality of life and care pathways by enabling remote monitoring and AI-driven risk prediction. Its platform combines patient and clinician input with predictive models to inform treatment decisions. The startup is women-led and founded in 2018 at the GPS coordinates of Cambridge. 52 North plans to use its recent funding to advance NeutroCheck through U.K. clinical trials and to pursue strategic partnerships with organisations such as the UK Sepsis Trust and Macmillan Cancer Support. The company positions health equity and improved outcomes at the heart of its solutions.

Participated · Seed · May 2024

Infinitopes combines AI-driven antigen discovery with high-efficiency viral vectors to build a scalable, off-the-shelf cancer vaccine platform. Its lead program, ITOP1, targets prevention of recurrence in oesophageal cancer and is entering a first-in-human, placebo-controlled Phase I/IIa study (VISTA) across multiple UK NHS university cancer centres. Supported by Cancer Research UK and embedded in Oxford University’s BioEscalator, the company has grown from three academic founders to roughly 20 full-time employees. Non-dilutive backing includes two maximum-size Innovate UK awards and an Innovative Licensing and Access Pathway passport from the MHRA. Beyond ITOP1, Infinitopes plans to expand its precision vaccine approach to additional solid tumours. To date the company has secured more than $35.1 million in equity financing from sector-focused investors such as Octopus Ventures, Amplify Bio, Cancer Research Horizons, Manta Ray Ventures and others. The fresh capital will fund the VISTA trial and further platform development.